NCT04401813View on ClinicalTrials.gov

Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

IBI308 200mg

Received IBI310 combined with sintilizumab 200mg

Trial Locations (1)

Unknown

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04401813 - Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter